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Simple Objective Detection of Human Lyme Disease Infection Using
Immuno-PCR and a Single Recombinant Hybrid Antigen
Micah D. Halpern,a Claudia R. Molins,b Martin Schriefer,b Mollie W. Jewetta
Burnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando, Florida, USAa; Diagnostic and Reference Laboratory, Bacterial Diseases
Branch, Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado, USAb

L

yme disease is the most commonly reported tick-borne illness
in the United States, with approximately 30,000 cases reported
to the Centers for Disease Control and Prevention (CDC) each
year (1). New preliminary estimates released by the CDC indicate
that the number of Americans diagnosed with Lyme disease each
year is closer to 300,000, which is roughly 10 times higher than the
annual reported number (2). This new estimate supports studies
published in the 1990s, which suggested that the number of cases
may be between 3- and 12-fold higher than the number of reported cases (3, 4), making Lyme disease a significant health concern in the United States. Accurate diagnosis provides a considerable obstacle for the clinical management of the disease and is
necessary in order to differentiate Lyme disease from other diseases with similar clinical presentation. Misdiagnosis is common
due to difficulties in detecting Borrelia burgdorferi, the causative
agent of Lyme disease (5). Although a wide range of laboratory
diagnostic approaches have been explored, the currently accepted
method utilizes the detection of serological responses to B. burgdorferi antigens (6).
The currently accepted method for diagnosing Lyme disease in
a clinical setting entails a two-tiered approach using a first-tier
enzyme-linked immunosorbent assay (ELISA), followed by a second-tier immunoblot assay for both IgM and IgG B. burgdorferispecific antibodies using whole-cell B. burgdorferi lysates, recombinant antigens, or various combinations, depending on the
commercial kit used (7). The ELISA provides an objective and
sensitive first-tier screen but lacks the specificity and broad strain
applicability (8) required for a standalone test. The second-tier
immunoblot provides a higher level of specificity but currently
requires somewhat subjective analysis due to its qualitative nature
and general lack of automation (9). A tiered approach has to date
provided the most effective means of diagnosing Lyme disease in a
clinical setting (7).

Other approaches for diagnosing Lyme disease have been developed, including live culture, PCR, and additional molecularbased approaches, with no method surpassing the effectiveness of
a serology-based approach. The detection of typical erythema
migrans (EM) can be sufficient for a clinical diagnosis of early
localized Lyme disease in the absence of laboratory tests (7). However, this manifestation is not present in all patients (7), further
highlighting the need for improved methods for early objective
diagnosis of Lyme disease. In our previous study, we demonstrated the use of immuno-PCR (iPCR) for detecting host-generated antibodies in a murine model, and we presented preliminary
data using serum samples collected from Lyme disease patients
and healthy controls (10). Our results indicated that iPCR using B.
burgdorferi whole-cell sonicates and a limited number of B. burgdorferi recombinant antigens provided higher sensitivity for detecting B. burgdorferi antibodies in infected mice and an equivalent sensitivity for detecting B. burgdorferi antibodies in Lyme
disease patient serum compared to both ELISA and the immunoblot (10).
It is well established that multiple antigens are required for an
accurate overall diagnosis of the multiple stages and types of Lyme
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A serology-based tiered approach has, to date, provided the most effective means of laboratory confirmation of clinically suspected cases of Lyme disease, but it lacks sensitivity in the early stages of disease and is often dependent on subjectively scored
immunoblots. We recently demonstrated the use of immuno-PCR (iPCR) for detecting Borrelia burgdorferi antibodies in patient serum samples that were positive for Lyme disease. To better understand the performance of the Lyme disease iPCR assay,
the repeatability and variability of the background of the assay across samples from a healthy population (n ⴝ 36) were analyzed.
Both of these parameters were found to have coefficients of variation of <3%. Using eight antigen-specific iPCR assays and positive call thresholds established for each assay, iPCR IgM and/or IgG diagnosis from Lyme disease patient serum samples (n ⴝ 12)
demonstrated a strong correlation with that of 2-tier testing. Furthermore, a simplified iPCR approach using a single hybrid
antigen and detecting only IgG antibodies confirmed the 2-tier diagnosis in the Lyme disease patient serum samples (n ⴝ 12).
Validation of the hybrid antigen IgG iPCR assay using a blinded panel of Lyme disease and non-Lyme disease patient serum samples (n ⴝ 92) resulted in a sensitivity of 69% (95% confidence interval [CI], 50% to 84%), compared to that of the 2-tier analysis
at 59% (95% CI, 41% to 76%), and a specificity of 98% (95% CI, 91% to 100%) compared to that of the 2-tier analysis at 97%
(95% CI, 88% to 100%). A single-tier hybrid antigen iPCR assay has the potential to be an improved method for detecting hostgenerated antibodies against B. burgdorferi.

Hybrid Antigen iPCR Detection of Lyme Disease

TABLE 1 iPCR DNA oligonucleotide sequences used in this study
Oligo IDa

Sequence (5= to 3=)b

T1
T1F
T1R
T1P
T2
T2F
T2R
T2P
1147
1148
1151
1152
1145
1146
1143
1144
1149
1150
1043
1044
1084
1085
1023

Template 1 (IgG coupled)
Template 1 forward
Template 1 reverse
Template 1 probe
Template 2 (IgM coupled)
Template 2 forward
Template 2 reverse
Template 2 probe
BBK19 F
BBK19 R
OspA F
OspA R
DbpA F
DbpA R
RevA F
RevA R
Crasp2 F
Crasp2 R
BBK50 F
BBK50R
DbpA_PEPC10 R
C6_PEPC10 F
C6 Bb R

Biotin-agcctcagaccaagccagacaactgcctcgtgacgttgctgcccctaccaacgtacccctacgagtcc
agcctcagaccaagccagac
ggactcgtaggggtacgttgg
FAM-actgcctcgtgacgttgctgcccct-BHQ1
Biotin-aggaggagggtcaagtcaccaacgctgctccaggccatcgtgctgatctggaccctggatcgagtga
aggaggagggtcaagtcacc
tcactcgatccagggtccag
MAX-acgctgctccaggccatcgtgctga-BHQ1
CGGGATCCttttcaaaagattctcgatcacg
ACGCCTCGAGtcaattgttaggtttttcttttcc
CGGGATCCaagcaaaatgttagcagcc
ACGCCTCGAGttattttaaagcgtttttaatttcatcaag
CGGGATCCggactaacaggagcaacaa
ACGCCTCGAGttagttatttttgcatttttcatcag
CGGGATCCaaagcatatgtagaagaaaagaaag
ACGCCTCGAGttaattagtgccctcttcg
CGGGATCCgatgttagtagattaaatcagagaaatatt
ACGCCTCGAGctataataaagtttgcttaatagctttataag
CGGGATCCatgtgtaaattatatgaaaagcttacaaataaatcgc
CCGCTCGAGttatctagagtccatatcttgcaattt
AGGTTTTTTTGGACTTTCTGCCACAACAGGgttatttttgcatttttcatcagtaaaagt
CCTGTTGTGGCAGAAAGTCCAAAAAAACCTatgaagaaggatgatcagattgc
ACGCGTCGACttacttcacagcaaactttccatc

a

ID, identification.
Uppercase letters indicate nontemplate sequence used for the addition of terminal restriction sites, epitope tags, or synthetic assembly. FAM, 6-carboxyfluorescein; BHQ1, black
hole quencher 1.

b

disease (7). Furthermore, it is critical that the antigens used for
diagnosis are demonstrated to have low cross-reactivity for diseases other than Lyme disease. The goals of this study were to (i)
determine the range of the levels of background detection of the
Lyme disease iPCR assays across a healthy human population, (ii)
explore a larger subset of antigens for assay sensitivity and specificity, and (iii) compare the performance of the optimized Lyme
disease iPCR protocol with that of the current 2-tier method of
Lyme disease diagnosis.
MATERIALS AND METHODS
Healthy human sera. The current study was approved by the University
of Central Florida’s institutional review board (UCF IRB) (FWA00000351
and IRB00001138). All procedures and investigators involved in the sample collection process were approved by the UCF IRB with Collaborative
Institutional Training Initiative (CITI) training. All donors provided
written consent to participate in the study. Sample collection was undertaken at the University of Central Florida campus. UCF is a diverse community of nearly 60,000 students and approximately 8,000 faculty and
staff members of various ages and ethnic and racial backgrounds. Individuals were included in the study if they had not been previously diagnosed
with and/or treated for Lyme disease, received a Lyme disease vaccination,
or lived within the past 10 years in a state with a high incidence of Lyme
disease (Connecticut, Delaware, Maine, Maryland, Massachusetts, Minnesota, New Hampshire, New Jersey, New York, Pennsylvania, Vermont,
Virginia, and Wisconsin). Approximately 10 ml of blood was sampled,
according to the IRB-approved protocol, from 36 individuals into serum
separator tubes, inverted five times to mix the clot activator with the
blood, and allowed to clot for ⱖ30 min. Serum fractions were collected by
centrifugation at 1,200 ⫻ g for 10 min. The serum was further clarified by
centrifugation at 9,100 ⫻ g for 5 min to remove any insoluble material and
stored at 4°C for short-term or ⫺80°C for long-term storage.
Lyme disease human serum panel. The CDC research panel I consisted of patient serum samples collected from 32 individuals, including
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patients with stage 1, 2, or 3 Lyme disease (n ⫽ 12), look-alike diseases,
including fibromyalgia, rheumatoid arthritis, multiple sclerosis, mononucleosis, syphilis, and severe periodontitis (n ⫽ 12), as well as healthy
individuals from areas of endemicity (n ⫽ 4) and nonendemicity (n ⫽ 4)
for Lyme disease. All Lyme disease patients were diagnosed by a physician,
stage 1 and 2 patients were confirmed by culture and/or PCR detection of
B. burgdorferi, and stage 3 patients were positive by two-tiered testing. The
CDC-recommended two-tiered testing algorithm (6) was performed using FDA-cleared assays for Lyme disease and consisted of a first-tier
whole-cell sonicate enzyme immunoassay (VIDAS Lyme IgM and IgG
polyvalent assay; bioMérieux, Inc., Durham, NC), followed by second-tier
IgM and IgG immunoblots (IB) (MarDx Diagnostics, Inc., Carlsbad, CA).
The blinded CDC research panel II consisted of serum samples collected
from 92 individuals, including patients with stage 1, 2, or 3 Lyme disease
(n ⫽ 32), look-alike diseases, including fibromyalgia, rheumatoid arthritis, multiple sclerosis, mononucleosis, syphilis, and severe periodontitis
(n ⫽ 36), as well as healthy individuals from areas of endemicity (n ⫽ 12)
and nonendemicity (n ⫽ 12) for Lyme disease. The laboratory support of
Lyme disease diagnosis was the same as for CDC research panel I. Prior to
analysis, all serum samples were clarified by centrifugation at 9,100 ⫻ g for
5 min to remove any insoluble material and put in the short-term storage
at 4°C.
Cloning and expression of recombinant antigens lacking GST fusion tags. Recombinant glutathione S-transferase (rGST)-BmpA and
rGST-OspC were constructed as previously described (10). In-frame glutathione S-transferase (GST) fusion proteins for BBK19, OspA, DbpA,
RevA, Crasp-2, and BBK50 were generated by PCR amplification of the
corresponding coding regions, without the signal sequences from B. burgdorferi genomic DNA, using primer pairs 1147 and 1148 (BBK19), 1151
and 1152 (OspA), 1145 and 1146 (DbpA), 1143 and 1144 (RevA),
1149 and 1150 (Crasp-2), or 1043 and 1044 (BBK50) engineered with
BamHI and SalI or XhoI restriction sites (Table 1) and Phusion polymerase (New England BioLabs, Ipswich, MA). The PCR products were purified (Qiagen, Valencia, CA), digested with the appropriate restriction enzymes (New England BioLabs), and cloned into BamHI- and SalI- or
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FIG 1 Schematic representation of the multiplex iPCR assay for detection of
Lyme disease host antibodies using recombinant antigens. (A) A recombinant
B. burgdorferi protein antigen coupled to magnetic beads was used to capture
B. burgdorferi-specific host-generated antibodies. A biotinylated DNA oligonucleotide reporter molecule coupled to a streptavidin-conjugated reporter
antibody was amplified by qPCR for detection and quantification. (B) The
same antigen-coupled beads were used to simultaneously capture IgM and IgG
host-generated antibodies, which were detected in a multiplex fashion using
isotype-specific secondary antibodies coupled to unique reporter oligonucleotides (T1 and T2) similarly amplified by qPCR for detection and quantification.

processing negative control that contained the TBST stock used for processing to determine the sample-to-sample contamination. Additionally,
each PCR run included calibrator plasmids carrying the cloned template
for the IgM or IgG reporter oligonucleotides that were used to account for
run-to-run variation in the threshold calculation between the PCR plates.
Briefly, the baseline was manually adjusted such that the Cq values for the
calibrator plasmids were set at a constant value for each plate to account
for minor variability in the threshold setting.
Positive threshold value and data analysis. The results of the Lyme
disease iPCR assay were reported as ⌬Cq values. The ⌬Cq value was calculated as the difference between the antigen-/isotype-specific background
threshold Cq value and the Cq value of the sample. The antigen-/isotypespecific background threshold Cq values were calculated as the mean Cq
value of each antigen-isotype combination for a group of 16 healthy individuals minus a specific multiple of the standard deviation (SD) of the
mean. The antigen-specific multiplier was set at a minimal value (1.9 to
6.6 for IgM and 3.1 to 5 for IgG), such that the samples from all individuals
without Lyme disease in CDC research panel I resulted in a Lyme disease
iPCR ⌬Cq value of ⬍0. Using these antigen-/isotype-specific thresholds,
any sample that resulted in a Lyme disease iPCR ⌬Cq of ⱖ0 was called
iPCR positive. The coefficient of variation (CV) was calculated as the ratio
of the SD to the mean. Assay sensitivity and specificity and the associated
95% confidence intervals were calculated using GraphPad Prism 5.0 for
Windows (GraphPad Software).

RESULTS

Lyme disease iPCR demonstrates strong within-assay precision
and reproducible background across a sample population of
healthy individuals. We previously demonstrated proof-of-principle for iPCR detection of human host-generated B. burgdorferi
antibodies using VlsE C6 peptide-coated magnetic beads and a
panel of serum samples (n ⫽ 36) from Lyme disease-positive and
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XhoI-digested pGEX-6P-1 (GE Healthcare, Piscataway, NJ) to generate
translational fusions with GST at the N terminus. Subsequent clones were
selected and the sequence confirmed by sequence analysis. pGEX-6P-1
plasmids carrying the bmpA, ospC, bbk19, ospA, dbpA, revA, crasp-2, and
bbk50 genes were transformed into Escherichia coli strain BL21 (Novagen,
Billerica, MA). Protein expression was induced by the growth of BL21 cells
containing the expression construct for each B. burgdorferi antigen in 50
to 100 ml of MagicMedia E. coli expression medium, according to the
manufacturer’s protocol (Invitrogen, Carlsbad, CA) for 24 h at 37°C with
aeration. Recombinant protein purification was performed according to
the procedures outlined in the Bulk GST purification module (GE Healthcare). The purified proteins were dialyzed in Tris-buffered saline (50 mM
Tris-HCl, 150 mM NaCl [pH 7.5]) overnight at 4°C using D-Tube dialyzers (EMD Millipore Chemicals, Philadelphia, PA) and two buffer exchanges to remove excess glutathione. The dialyzed proteins were subjected to protease cleavage of the GST tag overnight at 4°C, according to
procedures outlined in the PreScission protease kit (GE Healthcare).
Cleaved proteins were purified from GST and excess protease using two
rounds of Bulk GST purification (GE Healthcare) and collection of the
eluent. Purified proteins lacking a GST tag were concentrated using Amicon Ultra-2 centrifugal filter devices (EMD Millipore Chemicals) to a
volume of approximately 80 l and stored at 4°C. The total protein content was quantified by absorbance spectrophotometry at a wavelength of
280 nm. Recombinant protein purity and seroreactivity were determined
by Coomassie gel staining and immunoblot using infected mouse serum.
Briefly, 100 ng of each recombinant protein was separated by 12.5% polyacrylamide gel electrophoresis. For Coomassie staining, the gels were incubated in Imperial protein stain (Thermo Scientific, Rockford, IL) for 1
h and destained in deionized water for 1 h prior to imaging. For immunoblot analysis, the proteins were transferred to a nitrocellulose membrane, and the membrane was blocked in 5% skim milk and incubated for
1 h with mouse serum samples collected 3 weeks postinoculation with
wild-type B. burgdorferi, as previously described (10), diluted 1:200 in
Tris-buffered saline– 0.05% Tween (TBST) (pH 7.6), washed twice with
TBST, incubated with horseradish peroxidase (HRP)-conjugated goat
anti-mouse IgG/IgM (Chemicon International, Billerica, MA) for 1 h,
washed twice with TBST, and the signal was detected using the SuperSignal West Pico chemiluminescent substrate kit (Thermo Scientific).
Cloning and expression of the recombinant DOC antigen. An inframe glutathione S-transferase (GST) fusion protein for the DOC hybrid
protein was generated using two distinct PCR amplification steps. First,
the corresponding coding regions for DbpA and the C6 peptide of VlsE
(11) were amplified separately from B. burgdorferi strain B31 genomic
DNA, and the PEPC10 sequence (12) was added to each amplicon using
the primer pairs 1145 and 1084 (DbpA-PEPC10) and 1085 and 1023 (C6PEPC10), respectively, engineered with BamHI/SalI restriction sites (Table 1). Both PCR products were diluted 100-fold, combined, and synthetically assembled into the DOC construct by overlapping PCR using the
primer pairs 1145 and 1023. The final constructs were sequenced and
verified, and the recombinant protein was generated and purified as described above for the other B. burgdorferi antigens.
iPCR reagents, assay, and signal amplification. iPCR reagents were
prepared and the assays conducted as previously described (10), with
minor modifications. Briefly, iPCR assays were assembled in a two-sided
(sandwich) manner, as detailed in Fig. 1A, with the capability to simultaneously capture and report both IgM and IgG host-generated antibodies
(Fig. 1B). Recombinant antigens lacking fusion tags were used to coat
magnetic beads for host antibody capture using 10 to 20 g of antigen per
mg of beads. The beads were resuspended in 500 l TBST for secondary
antibody incubation. Signal amplification by real-time quantitative PCR
was accomplished as previously described (10), and the quantification
cycle (Cq) for each reaction was determined using a manual baseline determination (cycle 10 to 20) and a manual threshold setting of 1.0.
The PCR plate set-ups for all experiments included, in duplicate, a
PCR-negative template control consisting of water and an iPCR bead

Hybrid Antigen iPCR Detection of Lyme Disease

strong within-assay precision. (A) Serum collected from a single healthy individual was assayed 18 times by IgM/IgG multiplex iPCR using recombinant
DbpA antigen coupled to magnetic beads. Each dot represents a single replicate, and the horizontal line represents the mean Cq value for all replicates for
each isotype. The y axis represents the quantification cycle (Cq) determined by
real-time quantitative PCR. (B) The mean, standard deviation (SD), range,
and coefficient of variation (CV) (calculated as the ratio of the SD to the mean)
were calculated for both the IgM and IgG Cq values.

Lyme disease-negative patients and healthy controls (10). This
feasibility study was accomplished using a small number of samples from healthy controls (n ⫽ 5) to determine test efficiency and
background threshold levels. In an effort to establish a better understanding of the performance of the Lyme disease iPCR assay,
including the repeatability and the variability of the background of
the assay across a healthy population, the number of replicates and
overall sample size of healthy individuals were expanded. Prospective blood samples were collected from consenting individuals
without a history of Lyme disease under the approval of the University of Central Florida’s institutional review board. To assess
assay repeatability, a serum sample from a single healthy individual was tested 18 times using the same reagent preparation lots,
including DbpA antigen-coated beads and oligonucleotide-labeled secondary antibodies. The DbpA protein was selected as a
representative in vivo-expressed B. burgdorferi antigen. The results
of this analysis demonstrated low within-assay variability for both
the IgM- and IgG-specific detection reagents, as indicated by standard deviation values for each data set of 0.39 and 0.73, respectively, and coefficient of variation values for each data set of 1.34%
and 2.30%, respectively (Fig. 2).
To determine the variability in the background of the Lyme
disease iPCR assay across a healthy human population, the serum
samples from 36 healthy individuals were tested in duplicate using
magnetic beads coated with the DbpA antigen and the oligonucleotide-labeled IgM and IgG secondary antibodies used for the repeatability analysis. Similar to the within-sample repeatability
analysis, the results of the between-sample variability analysis
demonstrated a standard deviation across the population of 0.79
for the background detection of IgM antibodies and 0.84 for IgG
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FIG 3 Lyme disease immuno-PCR demonstrates reproducible background
across a healthy human population for both IgM and IgG isotypes using the
DbpA antigen. Serum samples from 36 healthy individuals were assayed in
duplicate by multiplex iPCR using both IgM (A) and IgG (B) secondary antibodies and recombinant DbpA antigen-coupled magnetic beads. Each dot
represents a single replicate per individual, with the horizontal lines representing the mean value for duplicate serum samples from each individual. The y
axis represents the quantification cycle (Cq) determined by real-time quantitative PCR. (C) The mean, standard deviation (SD), range, and coefficient of
variation (CV) (calculated as the ratio of the SD to the mean) is listed for each
isotype.

antibodies; the coefficients of variation were 2.66% and 2.63%,
respectively (Fig. 3).
Mean and standard deviation background values across a
population of healthy individuals are unique for each Lyme disease iPCR assay antigen-isotype combination. The analysis of
the Lyme disease iPCR assay repeatability and population variability using DbpA-coupled magnetic beads demonstrated that the
mean background value for the detection of IgM versus IgG antibodies differed by as much as ⬃2.5 Cq values (Fig. 2 and 3). Based
on this observation, we predicted that depending on the different
antigen used, each Lyme disease iPCR assay would result in a
distinct mean background Cq value. If true, this finding would
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FIG 2 Lyme disease immuno-PCR magnetic bead protocol demonstrates
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FIG 4 Immuno-PCR demonstrates low intra-antigen background variability
for an antigen panel across a healthy human population. Serum samples from
16 healthy individuals were assayed by multiplex iPCR for both IgM (A) and
IgG (B) host-generated antibodies against recombinant DbpA, BmpA, OspC,
BBK19, OspA, RevA, Crasp2, and BBK50 antigen-coupled magnetic beads.
Each point represents a single individual replicate, and the horizontal lines
represent the mean Cq values for all individuals for each antigen/isotype combination. Each antigen mean and standard deviation (SD) value is listed. The y
axis represents the quantification cycle (Cq) determined by real-time PCR. The
across-population mean, standard deviation, range, and coefficient of variation (CV) values are shown for each antigen/isotype combination.

Simplified single hybrid antigen iPCR detection of host-generated IgG antibodies alone confirms 2-tier results for a panel of
human serum samples. iPCR testing with the panel of eight B.
burgdorferi antigens showed strong potential as a Lyme disease
diagnostic method by reproducing the 2-tier test results for CDC
research panel I Lyme disease patient samples. Although successful, the use of multiple antigens tested against IgM and IgG increases test complexity by requiring the testing of a single sample
with multiple antigens. In an effort to further simplify the Lyme
disease iPCR approach, we theorized that a single hybrid antigen
composed of the immunogenic epitopes of multiple B. burgdorferi
antigens would provide results similar to those of testing with a
panel of whole individual antigens. To examine the applicability
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impact the determination of the background threshold setting for
the assay, making it necessary to assign a distinct background
threshold for each antigen-isotype combination. To test this hypothesis, we compiled a list from the literature of B. burgdorferi
proteins that are known or hypothesized to be seroreactive in humans (13–27). From this list, a subset of 8 B. burgdorferi antigens
was selected for further analysis in our assay due to their ability to
be produced in large quantities as recombinant in-frame N-terminal glutathione S-transferase (GST) fusion proteins in E. coli.
To eliminate any possibility of antibody cross-reactivity to the
GST tag, this sequence was proteolytically removed. The purity
and antigenicity of each recombinant antigen were demonstrated
by SDS-PAGE, followed by Coomassie brilliant blue staining and
immunoblot analysis using pooled sera collected from B. burgdorferi-infected mice (see Fig. S1 in the supplemental material).
Each antigen was coupled to magnetic beads and examined by
Lyme disease iPCR for both IgM and IgG background reactivities
across 16 serum samples collected from healthy individuals. As
predicted, all antigen-isotype combinations demonstrated unique
background values that ranged from a mean Cq of 26.09 to 32.46
for IgM and 25.30 to 36.62 for IgG and a standard deviation of 0.40
to 1.53 for IgM and 0.37 to 1.47 for IgG (Fig. 4).
Multiplex iPCR detection of IgM and/or IgG host response
antibodies against B. burgdorferi using a panel of antigens has
the potential for improved sensitivity compared to 2-tier testing. Most existing protocols for Lyme disease diagnostics require
the use of multiple antigens to diagnose the disease. In an effort to
further explore the application of iPCR as a Lyme disease diagnostic,
we sought to develop a similar methodology that utilizes a combination of results for different antigens to facilitate diagnosis. The
panel of eight B. burgdorferi antigens was tested against the CDC
research panel I collection of sera using multiplex iPCR for the
simultaneous detection of IgM and IgG host-generated antibodies. The same human serum panel was previously tested
according to CDC guidelines by a commercial enzyme-linked
immunosorbent assay (ELISA), followed by IgM and IgG immunoblot (IB), and classified for 2-tier testing status (see Table S1 in
the supplemental material). Samples were considered positive by
iPCR if they resulted in a ⌬Cq value that was ⱖ0 for IgM or IgG for
one or more of the eight antigens tested. The ⌬Cq value was calculated as the difference between the antigen-/isotype-specific
background threshold Cq value and the Cq value of the sample.
The antigen-/isotype-specific background threshold Cq values
were calculated as the mean Cq value of each antigen-isotype combination for a group of 16 healthy individuals minus a specific
multiple of the standard deviation (SD) of the mean (Fig. 4). Each
antigen-specific multiplier was set at a minimum value (1.3 to 6.6
for IgM and 2.8 to 5 for IgG; see Table S2 in the supplemental
material), such that the samples from all individuals without
Lyme disease in CDC research panel I resulted in a Lyme disease
iPCR ⌬Cq value of ⬍0. Using these criteria, iPCR testing provided
similar results to those of 2-tier testing for the Lyme disease patient samples, with one exception (see Table S1 in the supplemental material). A single early Lyme disease patient sample that was
deemed negative by 2-tier testing was positive by iPCR (see Table
S1, sample A4). It should also be noted that no single antigen
provided iPCR-positive results across all Lyme disease patient
samples, which comprised different stages and clinical presentations of disease.

Hybrid Antigen iPCR Detection of Lyme Disease

of a single hybrid antigen for iPCR detection of host-generated
antibodies against B. burgdorferi infection, we synthetically constructed a novel hybrid antigen composed of full-length DbpA,
the PEPC10 peptide (OspC) (12), and the C6 peptide (VlsE) (11),
referred to as the DOC antigen (Fig. 5A). Similar to the previous
eight recombinant antigens, we determined the protein purity and
seroreactivity toward B. burgdorferi-infected mouse sera of the
hybrid protein (see Fig. S1 in the supplemental material). The
range of the background reactivity of the DOC antigen in the iPCR
assay was determined using the serum from a group of 16 healthy
individuals (Fig. 5B). The results of the between-sample variability analysis demonstrated a standard deviation across the population of 0.57 for the background detection of IgM antibodies and
0.51 for the background detection of IgG antibodies; the coefficients of variation were 2.31% and 1.94%, respectively. Using
iPCR, we then tested the hybrid antigen in duplicate against the
CDC research panel I for IgM and IgG reactivity, utilizing the
results to establish the positive call threshold as described above.
The DOC antigen IgG results confirmed all 2-tier-positive results
(Fig. 6A). Interestingly, the Lyme disease iPCR assay using the
DOC antigen tested negative for the detection of host-generated
IgM antibodies for all human samples analyzed (Fig. 6B).
Although early, specific diagnosis is the primary goal for any
Lyme disease diagnostic, determining the stage of disease progres-
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FIG 6 The iPCR assay using the DOC hybrid antigen provides robust detection of Lyme disease. A serum panel composed of 32 samples and consisting of
Lyme-infected individuals both early (acute and convalescent) and late (neurologic and arthritis) stage, as well as look-alike diseases and healthy individuals from areas of endemicity and nonendemicity were tested in duplicate
using DOC iPCR for both IgG (A) and IgM (B) reactivity. Each dot represents
a single individual replicate, and the black horizontal lines represent the mean
Cq values for all individuals within each category. The filled circles represent
samples that were positive with 2-tier testing, and the open circles signify a
2-tier-negative status. A positive threshold value was established using a multiplier of the standard deviation (SD) above the mean value with the ⌬Cq
threshold (gray horizontal line) representing a value of zero. S1, stage 1; S2,
stage 2; S3, stage 3.

sion would provide additional information to aide in the treatment of the disease. It is logical to assume that the amount of
host-generated B. burgdorferi antibody will increase with further
disease progression. Due to the quantifiable nature of iPCR test-
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FIG 5 Development of a hybrid antigen for simple detection of Lyme disease.
The DOC antigen was assembled using full-length DbpA protein fused to the
PEPC10 (OspC) and the C6 (VlsE) peptides (A) and was tested by iPCR using
DOC-coated magnetic beads against 16 healthy individuals for IgM and IgG
for the range of the background reactivity (B). (B) Each dot represents a single
individual replicate, and the horizontal lines represent the mean Cq values for
all individuals for IgM and IgG. The mean, standard deviation (SD), range, and
CV values are also listed. The y axis represents the quantification cycle (Cq)
determined by real-time quantitative PCR.
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DISCUSSION

There is an urgent need to develop new tools for improved diagnosis of Lyme disease. This study describes an objective Lyme
disease diagnostic method using iPCR detection of host IgG antibody binding to a single recombinant hybrid antigen.
Repeatability is a key parameter of any newly developed diagnostic test that provides confidence the test will identify individuals as disease positive or negative in a reproducible manner
across the inherent variability of a human population. iPCR has
been shown to be a reproducible approach for detecting other
targets (28, 29), although this method generates a background
signal in the absence of the analyte being detected (30). The back-

1100

cvi.asm.org

ground signal has been attributed to nonspecific binding of the
oligonucleotide-labeled secondary antibody, similar to the results
observed for other immunodiagnostics (31). Although a number
of approaches have been proposed to minimize the level of background amplification (32–34), no approach to date has proven
successful at completely eliminating the background signal. For
diagnosing Lyme disease, we propose that the iPCR background
signal provides an intrinsic advantage due to the fact that a positive result is a relative measure above the established background
threshold, thereby limiting the potential contribution of contamination, whereas a positive result for standard PCR is an absolute
measure that can be highly sensitive to low-level laboratory contamination (7). The baseline level of amplification using iPCR for
a negative sample far surpasses any low-level laboratory contamination that commonly results in false-positive detection for PCRbased clinical diagnostic tests. As a result, the level of PCR contamination required to produce a false positive above background
for iPCR is orders of magnitude above that for standard PCR. In
addition, critical to the success of this approach is a constant background that remains consistent between sample replicates and is
standardized across a healthy human population.
In an effort to determine the consistency of the background
amplification for the technique, we tested the serum from a single
healthy individual over 18 replicates using iPCR and found the
standard deviations of the mean Cq values to be 0.39 and 0.73 for
IgM and IgG, respectively, with corresponding coefficients of variation of 1.34% and 2.30%, respectively. The accepted value for
PCR sampling error is ⬃1 Cq (35), and the coefficient of variation
for an ELISA-based test is considered good at ⬍15% (36). These
data indicate that our iPCR protocol can provide highly consistent
and repeatable results across multiple replicates of a single sample.
We proceeded to test serum samples collected from 36 healthy
individuals in duplicate for IgM and IgG reactivity using the same
antigen to determine the variability of the background across a
healthy population. As expected, compared to the within-sample
repeatability analysis, we observed a slightly higher standard deviation of the mean Cq values of 0.79 and 0.84 for IgM and IgG,
respectively, as well as slightly increased corresponding coefficients of variation of 2.66% and 2.63%, respectively. These data
demonstrate that the assay maintains strong repeatability even
when compounded with normal human population serum variability. Taken together, these results indicate that the background
variability for iPCR detection of host-generated antibodies within
and across a healthy human population is well within acceptable
levels for the technique.
Previous studies using recombinant antigens have indicated
that no single antigen tested to date has the capability to diagnose
Lyme disease across its multiple stages and disease manifestations
(7). A panel of eight antigens was generated for use in the iPCR
assay. These proteins were selected based on previous studies that
identified B. burgdorferi immunoreactive antigens (13–27). We
first examined the level of variability of the background amplification of each antigen across serum samples collected from
healthy individuals for both the IgM and IgG isotypes. Each antigen resulted in a unique background amplification mean and
standard deviation value for each antigen-isotype combination.
This indicated that each antigen-isotype combination performed
uniquely using the current iPCR protocol. These data provided
the necessary parameters, including the mean background Cq
value and the standard deviation of that mean for determining an
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ing, we hypothesized that the amount of anti-DOC host-generated IgG antibody correlates with disease stage. The mean ⫾ SD
iPCR value was ⫺1.61 ⫾ 0.36 for stage 1 acute early Lyme disease
patients, 0.67 ⫾ 0.38 for stage 1 convalescent early Lyme disease
patients, and 2.39 ⫾ 0.64 for stage 2/stage 3 Lyme disease patients,
for a total of n ⫽ 4 samples per group. These data may suggest a
correlation of increasing antibody capture with disease progression; however, further evaluation with an increased number of
clinically defined samples is required to support this finding. It
should also be noted that the number of EM rashes documented
for each patient showed no correlation with the iPCR value for B.
burgdorferi antibody detection (data not shown).
DOC hybrid antigen iPCR demonstrates robust sensitivity
and specificity for a blinded panel of human serum samples. The
initial success of DOC IgG iPCR with replicating 2-tier results for
a panel of 32 human serum samples provided strong evidence for
the application of our approach as a simplified Lyme disease diagnostic. We next sought to perform a larger-scale blinded validation analysis of our assay. The CDC research panel II, composed of
92 samples, including sera collected from patients with early Lyme
disease and EM (stage 1), early Lyme disease with neurological or
cardiac evidence of dissemination (stage 2), and patients with
Lyme arthritis (stage 3), as well as look-alike diseases and healthy
donors, was tested by iPCR for host-generated IgG antibodies to
the DOC hybrid antigen, and the results were compared to those
of the 2-tier test (Table 2). Using the background threshold Cq
value for DOC/IgG established above, overall, iPCR provided levels of sensitivity and specificity comparable to those of 2-tier testing (Fig. 7). iPCR replicated all 2-tier-positive results. Moreover,
iPCR provided detection of an additional three early Lyme disease
samples deemed negative by 2-tier testing, leading to an overall
sensitivity for iPCR of 69% (95% confidence interval [CI], 50% to
84%) compared to the sensitivity of 2-tier testing of 59% (95% CI,
41% to 76%). The difference in sensitivity was entirely for detecting stage 1 early Lyme disease samples, with sensitivity for iPCR of
55% (95% CI, 32% to 77%) and of 40% for 2-tier testing (95% CI,
19% to 64%) for this category of samples. iPCR and 2-tier testing
showed equivalent sensitivity for stage 2/stage 3 Lyme disease
samples of 92% (95% CI, 62% to 100%). iPCR detected only a
single false positive for a sample from a healthy control from an
area of endemicity (healthy endemic sample), resulting in a specificity of 98% (95% CI, 91% to 100%) compared to 2-tier testing,
which detected two false positives for look-alike diseases, providing a specificity of 97% (95% CI, 88% to 100%). For comparison,
the sensitivity and specificity for the ELISA first-tier portion of the
2-tier test were calculated to be 75% (95% CI, 57% to 89%) and
77% (95% CI, 64% to 87%), respectively.

Hybrid Antigen iPCR Detection of Lyme Disease

TABLE 2 iPCR using DOC/IgG demonstrates results equivalent to those of 2-tier testing for a panel of Lyme disease patient serum samples

Sample group
Lyme disease stage 2
Early Lyme-EMd

Lyme carditis

Lyme disease stage 3
Lyme arthritis

Non-Lyme
Fibromyalgia

Rheumatoid arthritis

Multiple sclerosis

Tier 2 bands detected for:

DOC IgG

iPCR

2-Tier

Tier 1 ELISA

IgM

IgG

B1
B2
B3
B4
B5
B6
B7
B8
B9
B10
B11
B12
B13
B14
B15
B16
B17
B18
B19
B20

2.24e
2.20
2.07
2.05
1.59
1.45
1.08
0.80
0.52
0.08
(0.08)
(0.27)
(0.58)
(0.91)
(1.00)
(1.01)
(1.22)
(1.48)
(1.50)
1.14

Pos
Pos
Pos
Pos
Pos
Pos
Pos
Pos
Pos
Pos
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Pos

Pos
Pos
Pos
Pos
Pos
Pos
Pos
Pos
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg

Pos
Pos
Pos
Pos
Pos
Pos
Pos
Pos
Pos
Equ
Pos
Neg
Pos
Pos
Neg
Neg
Neg
Equ
Neg
Pos

41, 39, 23
23
41, 39, 23
41
41, 23
41, 39, 23
41, 39, 23
41, 23
23

58, 41, 39, 23, 18
66, 45, 41, 39, 23, 18
41, 23
58, 45, 41, 39, 23, 18
41, 23
66, 45, 41, 39, 23, 18
41, 23
41
66, 41, 23

23

66, 41, 23
66

B21
B22
B23
B24
B25
B26

2.64
2.01
0.00
(0.26)
2.83
1.37

Pos
Pos
Pos
Neg
Pos
Pos

Pos
Pos
Pos
Neg
Pos
Pos

Pos
Pos
Pos
Neg
Pos
Pos

41, 23
41, 39, 23
41, 39, 23
41, 23
41, 39, 23
41, 39, 23

45, 41, 23
41, 39, 23
41, 23
41, 23
66, 45, 41, 23, 18
66, 45, 41, 23, 18

B27
B28
B29
B30
B31
B32

3.44
2.96
2.67
2.62
2.09
1.84

Pos
Pos
Pos
Pos
Pos
Pos

Pos
Pos
Pos
Pos
Pos
Pos

Pos
Pos
Pos
Pos
Pos
Pos

23
41
41, 23

93, 66, 58, 45, 41, 39, 30, 28, 23, 18
93, 66, 58, 41, 39, 30, 28, 23, 18
93, 66, 58, 45, 41, 39, 30, 28, 23, 18
66, 58, 45, 41, 39, 28, 23, 18
58, 41, 39, 23, 18
93, 66, 58, 41, 39, 30, 23, 18

B33
B34
B35
B36
B37
B38
B39
B40
B41
B42
B43
B44
B45
B46
B47
B48
B49
B50

(0.28)
(0.81)
(1.70)
(1.89)
(1.93)
(2.30)
(0.90)
(1.17)
(1.56)
(1.73)
(1.77)
(2.05)
(0.55)
(0.78)
(1.09)
(1.11)
(1.75)
(2.05)

Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg

Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Pos
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg

Neg
Neg
Neg
Neg
Neg
Neg
Pos
Neg
Neg
Pos
Neg
Neg
Neg
Pos
Neg
Neg
Neg
Neg

b

23
23
39, 23
23
23
41

23

39

41, 23
67
23
23
41
41, 23, 18

23
58, 41
41
41

41
41
41, 23

39, 23

41
41, 23

39
66
(Continued on following page)
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Lyme disease stage 2
Neuroborreliosis

Interpretation forc:

Sample
IDa

Halpern et al.

TABLE 2 (Continued)

Sample group
Mononucleosis

Syphilis

Healthy controls
From areas of endemicity

From areas of nonendemicity

Tier 2 bands detected for:

DOC IgG

iPCR

2-Tier

Tier 1 ELISA

B51
B52
B53
B54
B55
B56
B57
B58
B59
B60
B61
B62
B63
B64
B65
B66
B67
B68

(0.09)
(0.28)
(0.58)
(0.77)
(0.78)
(1.25)
(0.56)
(0.75)
(0.96)
(1.01)
(1.38)
(1.47)
(0.22)
(0.29)
(0.56)
(0.90)
(1.03)
(3.04)

Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg

Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Pos
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg

Neg
Pos
Pos
Equ
Neg
Neg
Pos
Pos
Pos
Pos
Pos
Neg
Neg
Neg
Neg
Neg
Neg
Neg

B69
B70
B71
B72
B73
B74
B75
B76
B77
B78
B79
B80
B81
B82
B83
B84
B85
B86
B87
B88
B89
B90
B91
B92

0.23
(0.04)
(0.53)
(0.87)
(0.87)
(1.11)
(1.16)
(1.37)
(1.42)
(1.49)
(1.95)
(2.47)
(0.53)
(0.60)
(0.78)
(0.80)
(0.86)
(0.90)
(1.09)
(1.15)
(1.17)
(1.77)
(2.06)
(2.09)

Pos
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg

Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg

Neg
Pos
Pos
Neg
Equ
Neg
Neg
Neg
Neg
Neg
Neg
Pos
Neg
Neg
Equ
Pos
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg

b

IgM

IgG
39
41, 39
41

41, 23

66, 58, 41
41
41

39, 23
41

45, 41
66

41
23
23

23
66
41, 23
41
45, 41

66, 41
23
23
41, 23

58, 41, 39, 18
41
41

58, 45
66, 58, 45, 41
41
41
23
23

a

ID, identification.
Values shown represent a ⌬Cq in reference to the antigen/isotype background threshold Cq value determined using an antigen-specific multiplier of the standard deviation (SD)
above the mean value for a set of healthy individuals for each antigen/isotype combination, as described in Materials and Methods. The values in parentheses represent negative
iPCR ⌬Cq values.
c
Two-tier results were established by standard ELISA and IgG/IgM immunoblot (IB) protocols. Pos, positive; Neg, negative; Equ, equivocal.
d
EM, erythema migrans.
e
Bold type indicates positive assay results/interpretations.
b

individual call threshold for each antigen-isotype combination. The
call thresholds were established as the mean background Cq value
minus a multiple of the standard deviation. The multiplier of standard deviation was unique for each antigen-isotype combination and
established based on the minimum multiplier that resulted in no
false-positive calls for the CDC research panel I, which served as the
training set for optimizing our assay. The ⌬Cq was calculated as the
established threshold call Cq minus the Cq value of the sample. A
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sample with a ⌬Cq value of ⱖ0 was deemed positive by iPCR. Using
the panel of eight antigens, this approach duplicated 2-tier testing
results with a single early Lyme patient sample (culture positive) testing positive by iPCR that was negative by 2-tier testing. Samples from
individuals in the later stages of disease (neurologic and arthritis)
tended to test positive for multiple antigens.
In addition to detecting the presence of host antibodies as laboratory support of an exposure to B. burgdorferi, it would be de-
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Severe periodontitis

Interpretation forc:

Sample
IDa

Hybrid Antigen iPCR Detection of Lyme Disease

sirable to link an antibody profile with the clinical stage (i.e., early
localized, early disseminated with neurological or cardiac involvement, or Lyme arthritis) of illness to better understand disease
progression. The results from the human serum panel iPCR testing classified both late Lyme arthritis samples as strongly positive
for IgG using the RevA and Crasp2 proteins, with all other categories of samples testing negative for the same two proteins. These
results suggest that these two proteins may specifically illicit an
immune response in a Lyme arthritis patient as opposed to those
in other stages of Lyme disease. However, analysis of a greater
number of clinically defined samples is required to further support these observations.
Limited studies have shown promising results using antigens
composed of multiple antigenic portions of various seroreactive
proteins to detect B. burgdorferi antibodies in human patient sera
(24, 37, 38). The demonstration of iPCR equivalency to 2-tier
testing using a panel of antigens led us to surmise that a more
simplified version of the protocol using a single hybrid antigen
was likely to be successful. Three antigens known to be seroreactive at different stages of the disease (DbpA, OspC, and VlsE) were
synthetically joined by combining the seroreactive peptide portions of OspC (39) and VlsE (40) with the full-length DbpA protein into a single recombinant hybrid antigen we termed DOC.
The mean background was established for 16 healthy individuals
using DOC and showed little variation (standard deviation, 0.57
and 0.51 for anti-B. burgdorferi IgM and IgG antibodies, respectively), similar to the results for the full-length antigens tested. The
DOC antigen was then used to test CDC research panel I for anti-B. burgdorferi IgM and IgG antibodies to establish a positive call
threshold. Using the positive call threshold, the DOC iPCR IgG
assay demonstrated results equivalent to those for 2-tier testing,
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FIG 7 DOC hybrid antigen IgG iPCR demonstrated sensitive and specific
detection of Lyme disease for a blinded serum panel. CDC research panel II
was tested in a blinded fashion using DOC iPCR for IgG reactivity. Each dot
represents a single individual replicate, and the black horizontal lines represent
the mean Cq values for all individuals within each category. The filled circles
represent samples that were positive with 2-tier testing, and the open circles
signify a 2-tier-negative status. A positive threshold value was established using
a multiplier of the standard deviation (SD) above the mean value, with the ⌬Cq
threshold (gray horizontal line) representing a value of zero. The sensitivity
and specificity values for iPCR, each tier, and combined 2-tier testing are listed.

with all 2-tier positives identified as positive by iPCR. The quantification of the ⌬Cq for Lyme disease patients showed a trend of
increasing average values from early Lyme acute (⫺1.61) to convalescent early Lyme (0.67) to late-stage Lyme (2.39), suggesting a
correlation in the amount of detectable B. burgdorferi antibody
with disease stage. Interestingly, DOC iPCR IgM was negative for
all samples tested, including Lyme disease patient samples. The
full-length DbpA antigen alone resulted in a low-positive IgM
iPCR value (0.69) for only a single Lyme disease patient sample.
iPCR testing using the full-length OspC antigen resulted in a
number of IgM iPCR-positive samples, suggesting that the antibodies detected in these samples may have resulted from OspC
epitopes other than the PEPC10 sequence. It is also possible that in
the context of the DOC hybrid antigen, the PEPC10 sequence
lacks the conformational epitope(s) required for IgM recognition.
It is well documented that the VlsE antigen primarily generates
IgG rather than IgM antibodies early in infection (41). Therefore,
it may not be surprising that the DOC antigen detects IgG antibodies only. These results indicate that testing only the IgG fraction using the DOC hybrid antigen was necessary to achieve a level
of sensitivity equivalent to that of 2-tier testing, which required
IgM for positive detection in some samples. Given the small sample size, these findings do not rule out the possibility that IgM
antibodies might be detected with the DOC iPCR assay in some
Lyme disease patient serum samples. Moreover, the additional
optimization of the hybrid antigen to include the specific detection of IgM antibodies may contribute to further improved sensitivity for detecting disease in patients with early Lyme disease.
Nonetheless, IgM detection has been problematic and controversial due to its contribution to false-positive results and the requirement that IgM testing be used only within the first 4 weeks of
infection (7), suggesting that an assay that does not use IgM may
represent an improvement over the current methods of testing for
Lyme disease. In addition, our data suggest that there exists the
potential to determine the stage of disease based on the ⌬Cq value
of the DOC iPCR assay, which represents another possible improvement over current Lyme disease diagnostics.
iPCR testing of the anti-B. burgdorferi IgG antibody fraction
using the DOC hybrid antigen was successful at duplicating the
2-tier testing results for a small panel of samples. We then proceeded to test a larger blinded panel of 92 samples composed of
serum samples from Lyme patients (early, early disseminated with
cardiac or neurological involvement, and Lyme arthritis), those
with look-alike diseases (fibromyalgia, mononucleosis, multiple
sclerosis, rheumatoid arthritis, severe periodontitis, and syphilis),
and healthy (from areas of endemicity and nonendemicity) individuals (CDC research panel II). iPCR demonstrated 69% sensitivity and 98% specificity compared to 59% and 97%, respectively,
for 2-tier testing. A single neurologic Lyme patient tested negative
by both iPCR and 2-tier testing. This result is most likely due to the
fact that the serum sample was taken 7 days post-erythema migrans (EM), which was likely too early in the infection process to
produce an adequate immune response.
Currently, the DOC hybrid antigen is composed of B. burgdorferi B31 sequences. Amino acid sequences can vary between strains
and species of Lyme disease borreliae by as much as 24% for VlsE
C6 (11), 10% for OspC PEPC10C (12), and 44% for DbpA (42).
This may be limiting if an individual is infected with other strains
or species. It is likely that the incorporation of additional protein/
peptide sequences from other species, such as Borrelia afzelii or
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